Tumor cell–specific exon 3‑deleted FOXP3 isoform promotes growth and metastasis via STAT3 in non‑small cell lung cancer
Open Access
- 7 July 2026
- journal article
- Published by Oxford University Press (OUP) in Life Medicine
- Vol. 5 (4) , lnag024
Abstract
Forkhead box P3 (FOXP3), the master regulator of regulatory T cells (Tregs), is aberrantly expressed in tumor cells, including lung cancer. Alternative splicing generates multiple isoforms, among which the full-length FOXP3 (FOXP3FL) and exon 3-deleted variant (FOXP3Δ3) are predominant. We identified FOXP3Δ3 as the major isoform in non-small cell lung cancer (NSCLC) tumor cells. FOXP3Δ3 expression was elevated in tumor tissues and correlated with larger tumor size and advanced T stage. Functional assays showed that tumoral FOXP3Δ3 enhanced proliferation, invasion, migration, stemness, and apoptosis resistance in NSCLC cells, exerting stronger effects than FOXP3FL. Knockdown of FOXP3Δ3 in NSCLC cells suppressed tumor growth in nude mice, confirming its oncogenic activity in vivo. Mechanistically, FOXP3Δ3 upregulated phosphorylated STAT3 and mesenchymal markers (N-cadherin, Vimentin, Snail), while reducing epithelial marker E-cadherin compared with FOXP3FL. Co-immunoprecipitation indicated these differences may arise from distinct STAT3 binding affinities. Additionally, FOXP3Δ3 decreased cisplatin-induced apoptosis, suggesting a role in chemoresistance. In summary, FOXP3Δ3 is the predominant oncogenic FOXP3 isoform in NSCLC tumor cells, promoting tumor cell progression and therapy resistance through STAT3 signaling. These findings highlight FOXP3Δ3 as a potential therapeutic target.Keywords
This publication has 37 references indexed in Scilit:
- Complexity and diversity of FOXP3 isoforms: Novel insights into the regulation of the immune response in metastatic breast cancerInternational Immunopharmacology, 2023
- The role of FOXP3 in non-small cell lung cancer and its therapeutic potentialsPharmacology & Therapeutics, 2022
- The emerging role of transcription factor FOXP3 in thyroid cancerReviews in Endocrine and Metabolic Disorders, 2021
- Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp)Medicinal Research Reviews, 2020
- Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung CancerJAMA, 2019
- The expression of FOXP3 and its role in human cancersBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2019
- Overexpression of the transcription factor FOXP3 in lung adenocarcinoma sustains malignant character by promoting G1/S transition gene CCND1Tumor Biology, 2015
- FOXP3 expression in tumor cells and implications for cancer progressionJournal of Cellular Physiology, 2012
- Forced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4+CD25– cellsEuropean Journal of Immunology, 2008
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001